Fig. 2.

Kaplan Meier survival curves estimating the cumulative proportion that experienced the primary endpoint at day 30, in the modified Intention-to-treat population. Cox regression model stratified by clinical center fitted to estimate the hazard ratio (HR) of primary endpoint in arm A vs arm B; 95% confidence intervals (CI) are reported. Primary endpoint: time to clinical improvement of 2 points on a 7-point category ordinal scale. Arm A: sarilumab plus standard of care. Arm B: standard of care.